Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) is a clinical trial[1].
Key Facts
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) is in the country of Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) — country (P17): United States[2].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s instance of is recorded as Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) — instance of (P31): clinical trial[3].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s start time is recorded as +2012-02-29T00:00:00Z[4].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s end time is recorded as +2016-07-31T00:00:00Z[5].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s main subject is recorded as Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) — main subject (P921): urinary incontinence[6].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s number of participants is recorded as {'unit': '1', 'amount': '+386'}[7].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s title is recorded as Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)[8].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s short name is recorded as ROSETTA[9].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+21'}[10].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s ClinicalTrials.gov ID is recorded as NCT01502956[11].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s research intervention is recorded as Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) — research intervention (P4844): botulinum toxin type A[12].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s clinical trial phase is recorded as Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) — clinical trial phase (P6099): phase III clinical trial[13].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s research site is recorded as Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) — research site (P6153): UNM Los Lunas[14].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s research site is recorded as Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) — research site (P6153): University of Pennsylvania[15].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s research subject recruitment status is recorded as Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) — research subject recruitment status (P8005): completed[16].
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)'s study type is recorded as Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) — study type (P8363): interventional study[17].